Early Development of CDX-1401, A Novel Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205, in Combination with Toll-like Receptor Agonists

Madhav V. Dhodapkar1; Mario Szoloi1; Ding Wang2; Ellen Chuang3; Richard Carvajal3; Harriet Kluger4; Venky Ramakrishna5; Laura Vitale3; Thomas Davis2; Ralph M. Steinman6; Tibor Keler2


BACKGROUND

Cancer-testis antigen NY-ESO-1

- Normal tissue expression restricted to germ cells (i.e. testis)
- Frequently expressed in a broad range of tumors including lung, breast, ovarian, bladder, liver cancers, melanoma and myeloma.
- Spontaneous immune responses to NY-ESO-1 have been reported in ~ half of patients with NY-ESO-1 expressing cancers.
- Approach under development in collaboration with Ludwig Institute for Cancer Research NY.

CDX-1401 contains the entire coding sequence for the anti-DEC-205 mAb (3G9) directly fused in-frame with the full coding sequence of NY-ESO-1. The antibody fusion protein is produced by transfected CHO cells.

NY-ESO-1 Antibody Responses

- Pre-existing anti-NY-ESO-1 antibody titers were noted in four patients; all had tumors expressing NY-ESO-1.
- A significant increase in titer was induced in 2 patients with pre-existing immunity; the other 2 had baseline titers >1,200,000.
- Humoral response was induced in 8/16 (50%) of the remaining patients; of these, 4/5 (80%) who received >1 treatment cycle achieved a humoral response.
- Responses were most frequent for the 1 mg dose and onset earlier for the 3 mg dose.

Indication: Malignancies known to express NY-ESO-1, progressive after available curative/salvage therapies.

OBJECTIVES: Safety, Immune response, Dose Selection, Anti-tumor activity

Study Treatment: CDX-1401 (0.1, 1.0, or 3.0 mg) administered intracutaneously once every two weeks x 4, plus the TLR7/8 agonist, resiquimod (250 mg of 0.2% gel), applied topically on the day of and the day after CDX-1401 administration.

Baseline Characteristics

- All Patients (n=20)
  - Male: 11 (55%)
  - Age (median [range]): 60 (48-79)
  - Cancer type (%): Melanoma 14 (70%), Ovarian 3 (15%), Other 3 (15%)
  - NY-ESO-1 Expression*: 6 (35%)

NY-ESO-1 Expression

- Tumor tissue analyzed by IHC and PCR at a central laboratory. Results not available for 3 patients.

Safety

- No dose-limiting toxicity (DLT)
- Treatment-related toxicities, all Grade 1-2, included administration site reaction (79%), fatigue (21%), decreased appetite (16%), nausea (11%), arthralgia (11%), and headache (11%).

Safety

- Targeting NY-ESO-1 to dendritic cells using CDX-1401 with topical resiquimod can induce robust NY-ESO-1 immunity in advanced cancer patients, including humoral responses, cellular responses with generation of both CD4+ and CD8+ T cells against multiple regions of the protein, and augmentation of existing immunity.
- CDX-1401 is well-tolerated with no DLT or Grade 3 toxicity.

CONCLUSIONS

- Targeting NY-ESO-1 to dendritic cells using CDX-1401 with topical resiquimod can induce robust NY-ESO-1 immunity in advanced cancer patients, including humoral responses, cellular responses with generation of both CD4+ and CD8+ T cells against multiple regions of the protein, and augmentation of existing immunity.
- CDX-1401 is well-tolerated with no DLT or Grade 3 toxicity.
- 6 patients with stable disease (range: 4.7 to 11.5+ months) have been treated, including 4 who received ≥3 cycles. The majority developed NY-ESO-1-specific immune responses.
- Additional cohorts will evaluate CDX-1401 with subcutaneous TLR agonists including poly-ICLC and/or resiquimod.